The PD‐L1 IHC companion diagnostic has been acknowledged for NSCLC patients undergoing ICI treatment, and positive PD‐L1 expression is associated with a higher response rate and prolonged survival during ICI therapy.30, 31. This evidence concerns the gene CD274 and non-small cell lung carcinoma.